UNSPSC 51292027: Sertraline hydrochloride

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C17H17Cl2N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UTI8907Y6X, chemically known as 1-naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-, hydrochloride, (1s-cis)- but more generally known as sertraline hydrochloride, which bears US NIH Compound Identifier 63009.

UNSPSC 51292027 Sertraline hydrochloride is a Commodity code that nominally covers a specific antidepressant pharmaceutical product, but recent state and local solicitations tagged with this code show minimal activity directly aligned with the code's actual scope. The one opportunity explicitly matching the code involves Seminole County, Florida's procurement of naloxone and drug deactivation systems—products entirely unrelated to sertraline—suggesting a mislabeling or cross-coding issue in the county's procurement system. The other two opportunities, a Texas Health and Human Services Commission Request for Information on direct-to-manufacturer prescription programs and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products, address pharmaceutical procurement more broadly but do not isolate sertraline as a target product.

Activity under this code shows limited recent relevance to sertraline-specific procurement. Issuing bodies include state health and human services agencies (Texas HHS Commission, Minnesota Department of Administration) and county governments (Seminole County, Florida), with cooperative purchasing vehicles such as MMCAP appearing alongside direct county solicitations. Geographic spread covers Texas, Minnesota, and Florida. The Minnesota MMCAP RFP (due March 26, 2026) seeks generic pharmaceutical manufacturers for multi-state distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and 10 percent on fixed pricing, while the Texas RFI (response deadline April 3, 2026) is exploratory market research on direct-to-manufacturer models rather than a formal competitive solicitation. The Seminole County IFB (due July 26, 2023, posted June 30, 2026) for naloxone and drug deactivation systems appears mislabeled under this code. Vendors pursuing sertraline supply to state and local health and human services systems should monitor broader pharmaceutical RFPs through cooperative purchasing alliances and state health agencies, as sertraline-specific solicitations do not currently surface under this commodity code.